ST6GALNAC4 and diabetes mellitus: DPP-IV inhibitors have been recently developed as a new class of drugs for the treatment of diabetes, because DPP-IV inhibits glucose metabolism by degrading incretin hormones that play an important role in insulin secretion [19].